Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.

Debie, Yana; Van Audenaerde, Jonas R M; Vandamme, Timon; Croes, Lieselot; Teuwen, Laure-Anne; Verbruggen, Lise; Vanhoutte, Greetje; Marcq, Elly; Verheggen, Lisa; Le Blon, Debbie; Peeters, Bart; Goossens, Maria E; Pannus, Pieter; Ariën, Kevin K; Anguille, Sébastien; Janssens, Annelies; Prenen, Hans; Smits, Evelien L J; Vulsteke, Christof; Lion, Eva; Peeters, Marc; van Dam, Peter A

doi:10.1158/1078-0432.CCR-22-2185

Article (Scientific journals)

Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.

Debie, Yana; Van Audenaerde, Jonas R M; Vandamme, Timon et al.

2023 • In Clinical Cancer Research, 29 (3), p. 635 - 646

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/343717

DOI
10.1158/1078-0432.CCR-22-2185

PubMed
36341493

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

635.pdf

Publisher postprint (5.31 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Antibodies, Viral; COVID-19 Vaccines; Immunity, Cellular; Cancer patients

Abstract :

[en] [en] PURPOSE: Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable with that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and patients with cancer. Because of the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in patients with cancer. EXPERIMENTAL DESIGN: A total of 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs. 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARS-CoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T-cell responses against SARS-CoV-2-specific S1 and S2 peptides. RESULTS: Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects [GMT 1,755.90 BAU/mL (95% CI, 1,276.95-2,414.48) vs. 1,495.82 BAU/mL (95% CI, 1,131.48-1,977.46)]. However, homologous-boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels. CONCLUSIONS: In patients with cancer who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.

Disciplines :

Immunology & infectious disease

Author, co-author :

Debie, Yana ^✱; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Santé publique vétérinaire ; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital (UZA), Edegem, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium

Van Audenaerde, Jonas R M ^✱; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium

Vandamme, Timon ^✱; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital (UZA), Edegem, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium

Croes, Lieselot ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium ; GeIntegreerd Kankercentrum Gent (IKG), AZ Maria Middelares, Gent, Belgium

Teuwen, Laure-Anne ; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital (UZA), Edegem, Belgium

Verbruggen, Lise ; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital (UZA), Edegem, Belgium

Vanhoutte, Greetje ; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital (UZA), Edegem, Belgium

Marcq, Elly ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium

Verheggen, Lisa ; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital (UZA), Edegem, Belgium

Le Blon, Debbie ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium

More authors (12 more)

^✱ These authors have contributed equally to this work.

Language :

English

Title :

Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.

Publication date :

01 February 2023

Journal title :

Clinical Cancer Research

ISSN :

1078-0432

eISSN :

1557-3265

Publisher :

American Association for Cancer Research Inc., United States

Volume :

Issue :

Pages :

635 - 646

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-22-2185/3221399/ccr-22-2185.pdf

Funders :

Kom op tegen Kanker

Funding text :

We kindly thank the B-VOICE and Tri-VOICE plus patients and HEAL-V participants for participation; the nursing staff members at the Day Care Unit of the Antwerp University Hospital and AZ Maria Middelares; and the staff members of the Biobank Antwerp and all recruiting physicians: Sevilay Altintas, Zwi Berneman, Sarah Debussche, Charlotte De Bondt, Ximena Elzo-Kraemer, Veerle Galle, Felix Gremonprez, Konstantinos Papadimitriou, Jo Raskin, Marika Rasschaert, Kirsten Saevels, Wiebren Tjalma, Xuan Bich Trinh, Christophe Van Berckelaer, Jan Van den Brande, Ann Van de Velde and Anke Verlinden. We are grateful to Leo Heyndrickx, Johan Michiels, and Betty Willems for neutralising antibody testing, to Hans De Reu, Stefanie Peeters, Carole Faghel, Celine Merlin, and Ho Wa Lau for T-cell analysis, and to the clinical biology study team for performing serologic analysis. We are thankful to Silke Raats, Isolde Van der Massen, Sanne Wouters, and Sven De Keersmaecker for logistic support and coordination and to Abraham Lin for proofreading of the manuscript. In addition, we thank the B-VOICE, Tri-VOICE plus, and HEAL-V study teams for patient inclusion and sample collection. This work was supported by the Belgian Government through Sciensano (grant nos. COVID-19_SC004, COVID-19_SC059, COVID-19_SC061), Kom op tegen Kanker (KOTK_UZA/ 2020/12604/1), Methusalem (FFB150082, FFB200035), and UA core facility funding (KF120000). T. Vandamme is holder of Senior Clinical Investigator grant 1803723N of the Research Foundation - Flanders (Belgium) (FWO).

Available on ORBi :

since 07 April 2026

Statistics

Number of views

40 (3 by ULiège)

Number of downloads

24 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S. The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor. Educate. Ann Oncol 2021;32:579–81.
Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol 2021;7:1133–40.
Peeters M, Verbruggen L, Teuwen L, Vanhoutte G, Vande Kerckhove S, Peeters B, et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open 2021;6:100274.
van Dam PA, Debie Y, Teuwen L, Verbruggen L, Vanhoutte G, Peeters B, et al. Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients. ESMO Open 2022; 7:100414.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021;398:2258–76.
Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021;385:661–2.
Gounant V, Ferre VM, Soussi G, Charpentier C, Flament H, Fidouh N, et al. Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol 2021;17:239–51.
Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med 2021;27:2002–11.
Rottenberg Y, Grinshpun A, Ben-Dov IZ, Oiknine Djian E, Wolf DG, Kadouri L. Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol 2022;8:300–1.
Debie Y, Vandamme T, Goossens ME, van Dam PA, Peeters M. Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in cancer patients. Eur J Cancer 2022;163:177–9.
Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022;376:e068632.
Mair MJ, Berger JM, Berghoff AS, Starzer AM, Ortmayr G, Puhr HC, et al. Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations. JAMA Oncol 2022;8:106–13.
Mairhofer M, Kausche L, Kaltenbrunner S, Ghanem R, Stegemann M, Klein K, et al. Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer. Cancer Cell 2021;39:1171–2.
Kaku CI, Champney ER, Normark J, Garcia M, Johnson CE, Ahlm C, et al. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/ mRNA-1273 vaccination. Science 2022;375:1041–7.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, et al. Immunogenicity and reactogenicity of vaccine boosters after Ad26.COV2.S priming. N Engl J Med 2022;386:951–63.
Powell AA, Power L, Westrop S, McOwat K, Campbell H, Simmons R, et al. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England. Euro Surveill 2021;26:2100634.
Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 2021;398:856–69.
Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet 2021;397:2043–6.
Mayr FB, Talisa VB, Shaikh O, Yende S, Butt AA. Effectiveness of homologous or heterologous Covid-19 boosters in veterans. N Engl J Med 2022;386:1375–7.
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022;386:1046–57.
Sewell HF, Agius RM, Stewart M, Kendrick D. Cellular immune responses to covid-19. BMJ 2020;370:m3018.
Cortes A, Casado JL, Longo F, Serrano JJ, Saavedra C, Velasco H, et al. Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments. Eur J Cancer 2022;166:229–39.
Gao Y, Cai C, Grifoni A, Muller € TR, Niessl J, Olofsson A, et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat Med 2022;28:472–6.
Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 2022;603: 488–92.
Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell 2018; 33:547–62.
Cuykx M, Mortele O, Jansens H, Schouwers S, Meskal A, Hoffbauer I, et al. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays. Diagn Microbiol Infect Dis 2021;101:115486.
Irsara C, Egger AE, Prokop W, Nairz M, Loacker L, Sahanic S, et al. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clin Chem Lab Med 2021;59:1453–62.
Mari€en J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, et al. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. J Virol Methods 2021;288:114025.
Markewitz R, Juhl D, Pauli D, G€org S, Junker R, Rupp J, et al. Kinetics of the antibody response to boostering with three different vaccines against SARSCoV-2. Front Immunol 2022;13:811020.
Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Alessio N, et al. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study. ESMO Open 2022;7:100458.
Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, Ãs̃terlev S, Kragh A, et al. Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination. Cancer Cell 2022;40: 338–9.
Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol 2022;94:1825–32.
Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARSCoV-2: Mutation, infectivity, transmission, and vaccine resistance. World journal of clinical cases 2022;10:1–11.
Chen J, Wang R, Gilby NB, Wei GW. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. ArXiv 2021.
Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci 2021;25:8019–22.
Poh XY, Tan CW, Lee IR, Chavatte JM, Fong SW, Prince T, et al. Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial. Clin Infect Dis 2022.
Auster O, Finkel U, Dagan N, Barda N, Laufer A, Balicer RD, et al. Short-term adverse events after the third dose of the BNT162b2 mRNA COVID-19 vaccine in adults 60 years or older. JAMA Netw Open 2022; 5:e227657.
Oosting SF, van der Veldt AAM, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans A-MC, et al. Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. Lancet Oncol 2022;23:833–5.
Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, Jabbour R, Hofbauer TM, Merrelaar A, et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern. Med. 2022;182:165–71.
Hope JL, Bradley LM. Lessons in antiviral immunity. Science 2021;371:464–5.
Kent SJ, Khoury DS, Reynaldi A, Juno JA, Wheatley AK, Stadler E, et al. Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? Nat Rev Immunol 2022;22:387–97.
Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, et al. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer 2022;10:e004766.
Vogel E, Kocher K, Priller A, Cheng CC, Steininger P, Liao BH, et al. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. EBioMedicine 2022;85:104294.
Zollner A, Watschinger C, R€ossler A, Farcet MR, Penner A, B€ohm V, et al. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine 2021;70:103539.
Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 2022;185:847–59.
Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, et al. Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. Eur J Cancer 2021;150:1–9.
Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K, et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat Commun 2021;12:2893.
Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med 2021;27:1530–5.
Parry H, Bruton R, Stephens C, Brown K, Amirthalingam G, Otter A, et al. Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people. Immun Ageing 2021; 18:34.
Parry H, Bruton R, Tut G, Ali M, Stephens C, Greenwood D, et al. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. The Lancet Healthy longevity 2021;2:e554–60.
Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol 2022; 23:186–93.
Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic-Sarac M, et al. Rituximabtreated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Br J Haematol 2022;197:697–708.
Kared H, Redd AD, Bloch EM, Bonny TS, Sumatoh H, Kairi F, et al. SARS-CoV-2-specific CD8þ T cell responses in convalescent COVID-19 individuals. J Clin Invest 2021;131:e145476.